Thyroid lobectomy is sufficient for differentiated thyroid cancer with upgraded risk after surgery

被引:3
|
作者
Choi, Soon Min [1 ]
Kim, Dong Gyu [2 ]
Lee, Ji-Eun [2 ]
Ho, Joon [2 ]
Kim, Jin Kyong [2 ]
Lee, Cho Rok [2 ]
Kang, Sang-Wook [2 ]
Lee, Jandee [2 ]
Jeong, Jong Ju [2 ]
Chung, Woong Youn [2 ]
Nam, Kee-Hyun [2 ]
机构
[1] Chung Ang Univ, Gwangmyeong Chung Ang Hosp, Dept Surg, Coll Med, Seoul, South Korea
[2] Yonsei Univ, Severance Hosp, Dept Surg, Yonsei Canc Ctr,Coll Med, Seoul, South Korea
关键词
Thyroid lobectomy (TL); recurrence; prognosis; thyroid cancer; TERT PROMOTER MUTATIONS; LYMPH-NODE METASTASIS; COMPLETION THYROIDECTOMY; PROGNOSTIC-FACTORS; BRAF V600E; PAPILLARY; CARCINOMA; ASSOCIATION; RECURRENCE; SURVIVAL;
D O I
10.21037/gs-22-158
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: It is difficult to reliably distinguish between American Thyroid Association (ATA) low-risk and intermediate-risk differentiated thyroid cancer (DTC) before surgery. Therefore, physicians are faced with a dilemma regarding the necessity and timing of completion total thyroidectomy (CT) after thyroid lobectomy (TL). We evaluated proper surgical methods by analyzing oncologic outcomes of TL in patients with DTC whose risk had been upgraded after surgery. Methods: We retrospectively reviewed the medical records of 1,702 patients with DTC who underwent TL and ipsilateral central lymph node (LN) dissection between January 2006 and December 2011. The patients were classified into Group A ( n=1,159; low risk; <= 5 central LN metastases or the absence of pathologic microscopic capsular invasion) and Group B (n=543; upgraded intermediate risk after surgery; >5 central LN metastases or the presence of pathologic microscopic capsular invasion). We analyzed their clinicopathological characteristics and recurrence-free survival. Results: All 32 patients who experienced recurrence underwent CT. After the first operation, the duration until reoperation in Groups A and B were 8.00 +/- 2.74 ( range, 3.42-12.17) and 5.10 +/- 3.09 (range, 1.25-11.67) years, respectively. There was no significant difference in recurrence rates, disease-related mortality rates, or 10-year recurrence-free survival rates between the two groups. The mean follow-up durations in Groups A and B were 10.22 +/- 1.58 and 10.13 +/- 1.47 years, respectively. Univariate analysis showed that sex, age, tumor size, multifocality, extrathyroidal extension (ETE), and number of central LN metastases were not associated with recurrence after TL, although the rate of central LN metastases was. Multivariate analysis showed that sex, age, tumor size, multifocality, ETE, central LN metastases, and the number of central LN metastases were not associated with recurrence after TL, although multifocality was. Conclusions: TL with prophylactic central compartment neck dissection (CCND) is sufficient for patients with DTC whose risk is upgraded after surgery because they have a good prognosis at long-term follow-up. Larger-scale randomized clinical trials are required to confirm our findings.
引用
收藏
页码:1451 / 1463
页数:13
相关论文
共 50 条
  • [1] Thyroid Lobectomy for Low to Intermediate Risk Differentiated Thyroid Cancer
    Hartl, Dana M.
    Guerlain, Joanne
    Breuskin, Ingrid
    Hadoux, Julien
    Baudin, Eric
    Al Ghuzlan, Abir
    Terroir-Cassou-Mounat, Marie
    Lamartina, Livia
    Leboulleux, Sophie
    [J]. CANCERS, 2020, 12 (11) : 1 - 18
  • [2] Frequency of Thyroid Hormone Replacement After Lobectomy for Differentiated Thyroid Cancer
    Schumm, Max A.
    Lechner, Melissa G.
    Shu, Michelle L.
    Ochoa, Joana E.
    Kim, Jiyoon
    Tseng, Chi-Hong
    Leung, Angela M.
    Yeh, Michael W.
    [J]. ENDOCRINE PRACTICE, 2021, 27 (07) : 691 - 697
  • [3] Use of Radioiodine after Thyroid Lobectomy in Patients with Differentiated Thyroid Cancer: Does It Change Outcomes?
    Kiernan, Colleen M.
    Parikh, Alexander A.
    Parks, Lee L.
    Solorzano, Carmen C.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2015, 220 (04) : 617 - 625
  • [4] Unilateral Multifocality Is Not a Risk Factor for Recurrence After Thyroid Lobectomy: A Study of 1,684 Patients With Differentiated Thyroid Cancer
    Cho, Jin-Seong
    Kim, Hee Kyung
    [J]. IN VIVO, 2023, 37 (04): : 1802 - 1808
  • [5] Use of Radioiodine after Thyroid Lobectomy in Patients with Differentiated Thyroid Cancer: Does It Change Outcomes? Discussion
    Perrier, Nancy
    Snyder, Samuel
    Carneiro-Pla, Denise M.
    Rosen, Jennifer
    Kiernan, Colleen M.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2015, 220 (04) : 625 - 627
  • [6] Controversy: For or against thyroid lobectomy in &gt; 1 cm differentiated thyroid cancer?
    Menegaux, Fabrice
    Lifante, Jean-Christophe
    [J]. ANNALES D ENDOCRINOLOGIE, 2021, 82 (02) : 78 - 82
  • [7] Management of Thyroid Nodules and Surgery for Differentiated Thyroid Cancer
    Iyer, N. G.
    Shaha, A. R.
    [J]. CLINICAL ONCOLOGY, 2010, 22 (06) : 405 - 412
  • [8] Well-differentiated thyroid cancer: Thyroidectomy or lobectomy?
    Kluijfhout, Wouter P.
    Rotstein, Lorne E.
    Pasternak, Jesse D.
    [J]. CANADIAN MEDICAL ASSOCIATION JOURNAL, 2016, 188 (17-18) : E517 - E520
  • [9] Thyroid Hormone Supplementation Therapy for Differentiated Thyroid Cancer After Lobectomy: 5 Years of Follow-Up
    Kim, Soo Young
    Kim, Hee Jun
    Kim, Seok-Mo
    Chang, Hojin
    Lee, Yong Sang
    Chang, Hang-Seok
    Park, Cheong Soo
    [J]. FRONTIERS IN ENDOCRINOLOGY, 2020, 11
  • [10] Extent of surgery for intermediate risk well differentiated thyroid cancer
    Beenken, S
    Roye, D
    Weiss, H
    Sellers, M
    Urist, M
    Diethelm, A
    Goepfert, H
    [J]. AMERICAN JOURNAL OF SURGERY, 2000, 179 (01): : 51 - 56